You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global and United States Myelodysplastic Syndrome (MDS) Drugs Market Size, Status and Forecast 2020-2026

Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability of and access to novel treatments in major countries provides strong commercial opportunities to the market.
Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Drugs Market
The global Myelodysplastic Syndrome (MDS) Drugs market size is projected to reach US$ 2094.1 million by 2026, from US$ 1499.3 million in 2020, at a CAGR of 5.7% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myelodysplastic Syndrome (MDS) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myelodysplastic Syndrome (MDS) Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myelodysplastic Syndrome (MDS) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myelodysplastic Syndrome (MDS) Drugs market.
Myelodysplastic Syndrome (MDS) Drugs Breakdown Data by Type
Hypomethylating Agents
Immunomodulatory Drugs
Anti-anemics
Myelodysplastic Syndrome (MDS) Drugs Breakdown Data by Application
Original
Generics
Based on regional and country-level analysis, the Myelodysplastic Syndrome (MDS) Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Myelodysplastic Syndrome (MDS) Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Celgene
Amgen
Otsuka
Takeda
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Hypomethylating Agents
1.2.3 Immunomodulatory Drugs
1.2.4 Anti-anemics
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Application: 2020 VS 2026
1.3.2 Original
1.3.3 Generics
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Perspective (2015-2026)
2.2 Global Myelodysplastic Syndrome (MDS) Drugs Growth Trends by Regions
2.2.1 Myelodysplastic Syndrome (MDS) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myelodysplastic Syndrome (MDS) Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome (MDS) Drugs Players by Market Size
3.1.1 Global Top Myelodysplastic Syndrome (MDS) Drugs Players by Revenue (2015-2020)
3.1.2 Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Players (2015-2020)
3.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome (MDS) Drugs Revenue
3.4 Global Myelodysplastic Syndrome (MDS) Drugs Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome (MDS) Drugs Revenue in 2019
3.5 Key Players Myelodysplastic Syndrome (MDS) Drugs Area Served
3.6 Key Players Myelodysplastic Syndrome (MDS) Drugs Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome (MDS) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myelodysplastic Syndrome (MDS) Drugs Breakdown Data by Type (2015-2026)
4.1 Global Myelodysplastic Syndrome (MDS) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Type (2021-2026)

5 Myelodysplastic Syndrome (MDS) Drugs Breakdown Data by Application (2015-2026)
5.1 Global Myelodysplastic Syndrome (MDS) Drugs Historic Market Size by Application (2015-2020)
5.2 Global Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Myelodysplastic Syndrome (MDS) Drugs Market Size (2015-2026)
6.2 North America Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2015-2020)
6.3 North America Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2015-2020)
6.4 North America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size (2015-2026)
7.2 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2015-2020)
7.3 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2015-2020)
7.4 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe

8 China
8.1 China Myelodysplastic Syndrome (MDS) Drugs Market Size (2015-2026)
8.2 China Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2015-2020)
8.3 China Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2015-2020)
8.4 China Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific

9 Japan
9.1 Japan Myelodysplastic Syndrome (MDS) Drugs Market Size (2015-2026)
9.2 Japan Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2015-2020)
9.3 Japan Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2015-2020)
9.4 Japan Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Southeast Asia
10.1 Southeast Asia Myelodysplastic Syndrome (MDS) Drugs Market Size (2015-2026)
10.2 Southeast Asia Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2015-2020)
10.3 Southeast Asia Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2015-2020)
10.4 Southeast Asia Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa

11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Details
11.1.2 Celgene Business Overview
11.1.3 Celgene Myelodysplastic Syndrome (MDS) Drugs Introduction
11.1.4 Celgene Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2015-2020))
11.1.5 Celgene Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Myelodysplastic Syndrome (MDS) Drugs Introduction
11.2.4 Amgen Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2015-2020)
11.2.5 Amgen Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Details
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Myelodysplastic Syndrome (MDS) Drugs Introduction
11.3.4 Otsuka Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2015-2020)
11.3.5 Otsuka Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Myelodysplastic Syndrome (MDS) Drugs Introduction
11.4.4 Takeda Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2015-2020)
11.4.5 Takeda Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
  • FORMAT: PDF
  • PUBLISHED DATE: Aug, 2020
  • NO OF PAGES: 128